MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.25
+0.06
+0.45%
Opening 15:27 08/10 EDT
OPEN
12.27
PREV CLOSE
12.19
HIGH
12.47
LOW
12.18
VOLUME
314.55K
TURNOVER
--
52 WEEK HIGH
47.10
52 WEEK LOW
9.24
MARKET CAP
912.92M
P/E (TTM)
-6.1425
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYGN stock price target is 15.57 with a high estimate of 30.00 and a low estimate of 8.00.

EPS

MYGN News

More
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020
SALT LAKE CITY, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal fourth-quarter 2020 sales and earnings conference call with investors and a
GlobeNewswire · 4d ago
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 6d ago
Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
SALT LAKE CITY, July 31, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that Medicare has expanded coverage for BRACAnalysis® CDx for men with prostate cancer who are eli
GlobeNewswire · 07/31 11:05
Myriad Genetics's new technology improves performance of its Prequel NIPS
Myriad Genetics (MYGN +0.5%) has launched its proprietary AMPLIFY technology, which further increases the performance of its Prequel noninvasive prenatal s
seekingalpha · 07/29 19:48
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY™ technology, which further increases the per
GlobeNewswire · 07/29 11:05
Myriad Announces Launch Of New Radiographic Progression Prognostic Tool, Adding To Clinical Value Of Vectra
SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now
Benzinga · 07/28 11:09
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®
Example 1: The Vectra Score correlates to the risk of radiographic progression Example 1: The Vectra Score correlates to the risk of radiographic progressionSALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in mol
GlobeNewswire · 07/28 11:05
Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.
Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of DirectorsSALT LAKE CITY, July 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad”
GlobeNewswire · 07/22 11:05

Industry

Medical Equipment, Supplies & Distribution
-0.48%
Healthcare Equipment & Supplies
-0.41%

Hot Stocks

Symbol
Price
%Change

About MYGN

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.
More

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.